Four KOSDAQ Firms Unveil Third-Party Share Sales in Single-Day Wave

On July 6, four companies listed on South Korea’s tech-heavy KOSDAQ market simultaneously disclosed plans to raise capital through third-party allotment share issues, a clustered burst of financing activity that together points to roughly 54 billion won ($40 million range) in new equity commitments. The deals span biotech, telecommunications and pharmaceuticals, and in at least one case the fundraising is tied directly to a strategic investor’s own acquisition filing.

What Was Disclosed

Third-party allotment (제3자배정) is a private-placement mechanism in which a company issues new shares to designated outside investors rather than to existing shareholders. It is a common route for KOSDAQ firms seeking fast access to operating capital or a strategic partner, and the four disclosures reviewed here share that structure while differing sharply in scale and purpose.

• Sejong Telecom disclosed the largest raise of the group at 28 billion won, earmarked for operating funds, with the shares allotted to Sejong.
• Newon followed at roughly 19 billion won, designated in part for funds to acquire securities in another corporation, with KPM Tech named as the investor.
• Telcon RF Pharma disclosed approximately 5 billion won for operating capital, allotted to Evercore Investment Holdings.
• K-BioLabs disclosed the smallest raise, about 2 billion won for operating funds and related purposes, allotted to Mirae I&G.

The KPM Tech–Newon Link

The Newon transaction is the one deal in the cluster corroborated from both sides of the table. While Newon disclosed the incoming 19 billion won placement, a separate regulatory filing lodged through the Financial Supervisory Service’s DART electronic disclosure system shows KPM Tech itself declaring a decision to acquire stock and equity securities in another corporation. That acquirer-side disclosure confirms KPM Tech’s role as the designated investor rather than leaving it to a single press account, and it signals that the placement is a deliberate equity stake rather than a passive cash injection.

The reciprocal nature of the filings matters: Newon’s stated use of proceeds includes funds to acquire securities in yet another entity, suggesting the capital may be part of a broader chain of cross-holdings rather than a self-contained recapitalization.

Why the Clustering Is Notable

Same-day clusters of third-party allotments are not unusual on KOSDAQ, where smaller-cap issuers frequently turn to private placements when public rights offerings would be slower or dilutive to sentiment. The concentration on a single disclosure date, however, underscores how routinely growth-stage Korean firms lean on designated outside investors for working capital. Three of the four issuers—Sejong Telecom, Telcon RF Pharma and K-BioLabs—explicitly cited operating funds as the primary use, a pattern that typically reflects near-term liquidity needs rather than expansion financing.

For investors, the key variables not resolved by the initial disclosures are the issue price, the resulting dilution, and any lock-up terms on the newly issued shares—details that determine whether these placements strengthen the issuers or simply defer financing pressure. What is confirmed at this stage is the intent: four KOSDAQ boards independently committed to bringing in outside equity on the same day, and in the Newon case, the incoming investor has already filed its side of the deal.